Horizon Therapeutics Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Horizon Therapeutics ha aumentado sus beneficios a una tasa media anual de 32.8%, mientras que los beneficios de la industria de Biotechs han experimentado un crecimiento de 12.7% anual. Los ingresos han ido creciendo a una tasa media de 28.5% al año. La rentabilidad financiera de Horizon Therapeutics es de 8.2%, y sus márgenes netos son de 12%.

Información clave

32.8%

Tasa de crecimiento de los beneficios

30.0%

Tasa de crecimiento del BPA

Crecimiento de la industria Biotechs	17.0%
Tasa de crecimiento de los ingresos	28.5%
Rentabilidad financiera	8.2%
Margen neto	12.0%
Última actualización de beneficios	30 Jun 2023

Actualizaciones de resultados anteriores recientes

Recent updates

These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Nov 25

Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Aug 04

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Aug 02

Horizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven Growth

Jul 31

Horizon gets FDA approval for Krystexxa's use with methotrexate for uncontrolled gout

Jul 08

Desglose de ingresos y gastos
Beta

Cómo gana y gasta dinero Horizon Therapeutics. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).

Historial de beneficios e ingresos

NasdaqGS:HZNP Ingresos, gastos y beneficios (USD Millions)
Fecha	Ingresos	Beneficios	Gastos G+A	Gastos de I+D
30 Jun 23	3,644	438	1,659	516
31 Mar 23	3,576	372	1,623	469
31 Dec 22	3,629	521	1,543	438
30 Sep 22	3,701	574	1,592	422
30 Jun 22	3,813	765	1,526	354
31 Mar 22	3,769	862	1,511	391
31 Dec 21	3,226	534	1,442	345
30 Sep 21	2,957	552	1,297	315
30 Jun 21	2,557	518	1,190	254
31 Mar 21	2,187	280	1,029	195
31 Dec 20	2,200	390	973	129
30 Sep 20	1,819	792	880	122
30 Jun 20	1,518	517	827	161
31 Mar 20	1,376	592	772	109
31 Dec 19	1,300	573	696	103
30 Sep 19	1,292	82	686	94
30 Jun 19	1,282	97	674	91
31 Mar 19	1,264	77	679	87
31 Dec 18	1,208	-38	687	83
30 Sep 18	1,126	-178	680	-65
30 Jun 18	1,073	-275	674	-68
31 Mar 18	1,059	-460	661	70
31 Dec 17	1,056	-350	655	66
30 Sep 17	1,092	-495	680	218
30 Jun 17	1,029	-437	653	213
31 Mar 17	997	-212	626	61
31 Dec 16	981	-166	604	61
30 Sep 16	915	-12	517	49
30 Jun 16	933	-3	496	47
31 Mar 16	849	14	460	45
31 Dec 15	757	40	438	42
30 Sep 15	616	-16	330	33
30 Jun 15	465	-17	302	26
31 Mar 15	358	-77	241	21
31 Dec 14	297	-264	209	17
30 Sep 14	223	-335	182	14
30 Jun 14	172	-342	125	11
31 Mar 14	117	-333	111	11
31 Dec 13	74	-149	92	10
30 Sep 13	50	-70	85	12
30 Jun 13	32	-82	81	14
31 Mar 13	25	-86	74	15
31 Dec 12	19	-88	69	17

Ingresos de calidad: HZNP tiene un gran one-off loss de $131.0M impacto en sus últimos 12 meses de resultados financieros a 30th June, 2023.

Margen de beneficios creciente: Los actuales márgenes de beneficio(12%) de HZNP son inferiores a los del año pasado (20.1%).

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Tendencia de beneficios: HZNP ha pasado a ser rentable en los últimos 5 años, con un crecimiento de los beneficios de 32.8% al año.

Acelerando crecimiento: HZNP ha tenido un crecimiento negativo de los beneficios en el último año, por lo que no puede compararse con su media de 5 años.

Beneficios vs. Industria: HZNP tuvo un crecimiento negativo de los beneficios (-42.7%) durante el año pasado, lo que dificulta la comparación con la media de la industria Biotechs (-8.9%).

Horizon Therapeutics Resultados de beneficios anteriores

Pasado controles de criterios 1/6

Información clave

Actualizaciones de resultados anteriores recientes

Horizon Therapeutics Public Limited Company to Report Q2, 2023 Results on Aug 08, 2023

Horizon Therapeutics Public Limited Company to Report Q4, 2022 Results on Mar 01, 2023

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Horizon Therapeutics Public Limited Company to Report Q3, 2022 Results on Nov 02, 2022

Horizon Therapeutics Public Limited Company Reports Impairment of Goodwill for the Second Quarter Ended June 30, 2022

Horizon Therapeutics Public Limited Company to Report Q2, 2022 Results on Aug 03, 2022

Recent updates

Health Canada Approves Horizon Therapeutics plc 's UPLIZNA® (inebilizumab for injection) for the Treatment of Neuromyelitis Optica Spectrum Disorders

Horizon Therapeutics Public Limited Company Files Form 15

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Horizon Therapeutics Public Limited Company(NasdaqGS:HZNP) dropped from S&P Global BMI Index

Horizon Therapeutics Public Limited Company Announces New Analysis of Adhering to Uninterrupted Full Course of Treatment with Tepezza to Support Thyroid Eye Disease Patient Outcomes

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of Bempikibart for Severe Alopecia Areata

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Horizon Therapeutics Public Limited Company to Report Q2, 2023 Results on Aug 08, 2023

Horizon Therapeutics plc Announces New Analysis of MRI Findings Shows UPLIZNA®? (inebilizumab-cdon) Reduced the Formation of Subclinical Spinal Cord Lesions in People with Neuromyelitis Optica Spectrum Disorder

Horizon Therapeutics plc Announces Tepezza® (Teprotumumab) Approved in Brazil for the Treatment of Active Thyroid Eye Disease

Horizon Therapeutics plc Announces Positive Topline Data from Phase 3 Clinical Trial (Optic-J) in Japan

Horizon Therapeutics plc Announces Additional Data from Phase 4 TEPEZZA® (teprotumumab-trbw) Clinical Trial Presented at the Endocrine Society Annual Meeting Reinforces Efficacy in People with Thyroid Eye Disease (TED) Regardless of Disease Activity or Duration

Horizon Therapeutics plc Announces the Publication of New Analysis from the N-MOmentum Clinical Trial of UPLIZNA Demonstrating the Utility of A Robust Assay Process

Horizon Therapeutics plc Announces Data from the Teprotumumab Phase 4 Clinical Trial in Patients with Chronic/Low CAS Thyroid Eye Disease

Horizon Therapeutics plc Announces the Publication of New Data from the Phase 3 N-MOmentum Pivotal Trial of UPLIZNA

Horizon Therapeutics plc Announces Presentations At the 2023 Eular European Congress of Rheumatology Highlight New Results from Phase 2 Trial Evaluating Dazodalibep in Sjögren’S Syndrome

Horizon Therapeutics Public Limited Company to Report Q4, 2022 Results on Mar 01, 2023

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint in the Second Study Population

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating Daxdilimab for the Treatment of Discoid Lupus Erythematosus

Amgen Inc. (NasdaqGS:AMGN) entered into a transaction agreement to acquire Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) for $27.1 billion.

Amgen Reportedly in Advanced Talks to Buy Horizon Therapeutics

Horizon Therapeutics plc Announces First Subject Dosed in Phase 1 Trial Evaluating HZN-457 for the Treatment of Gout

Investor sentiment improved over the past week

These 4 Measures Indicate That Horizon Therapeutics (NASDAQ:HZNP) Is Using Debt Safely

Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (Optic-J) in Japan Evaluating Tepezza® for the Treatment of Active Thyroid Eye Disease

Insufficient new directors

Horizon Therapeutics plc Announces That Month 12 Data from the Mirror Randomized Controlled Trial of Krystexxa® (Pegloticase) Injection

Horizon Therapeutics plc Announces That Month 12 Data from the Mirror Randomized Controlled Trial of Krystexxa® (Pegloticase) Injection

Investor sentiment improved over the past week

Horizon Therapeutics Public Limited Company Announces Data Support the Use of KRYSTEXXA (Pegloticase) Injection with Methotrexate to Treat Uncontrolled Gout in People with Mild-To-Moderate Chronic Kidney Disease

Executive VP & Chief Strategy Officer exercised options and sold US$348k worth of stock

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Horizon Therapeutics Public Limited Company Revises Earnings Guidance for the Full Year 2022

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ADX-914 for Atopic Dermatitis

Horizon Therapeutics plc Announces New Data from Two Analyses of the Uplizna Phase 3 Pivotal Trial Presented At the 38(Th) Congress of the European Committee for Treatment and Research in Multiple Sclerosis (Ectrims 2022), Oct. 26-28 in Amsterdam

Horizon Therapeutics Public Limited Company to Report Q3, 2022 Results on Nov 02, 2022

Horizon Therapeutics plc Completes Enrollment for Phase 4 Trial of TEPEZZA® (Teprotumumab-Trbw) in Adults with Chronic/Low Clinical Activity Score (Cas) Thyroid Eye Disease (Ted)

Horizon pays HemoShear milestone payment under pact to develop gout therapies

Horizon Therapeutics plc Announces Data from the MIRROR Randomized Controlled Trial of KRYSTEXXA® (pegloticase) Injection with Methotrexate Published in Arthritis & Rheumatology

Horizon Therapeutics plc Announces Phase 2 Trial Evaluating Dazodalibep for the Treatment of Sjögren’s Syndrome Meets Primary Endpoint

Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP) announces an Equity Buyback for $500 million worth of its shares.

Horizon Therapeutics announces $500M buyback program

Horizon Therapeutics to expand footprint in Ireland

Is Horizon Therapeutics (NASDAQ:HZNP) A Risky Investment?

Horizon Therapeutics: This Core Biotech Company Is On Sale

Consensus revenue estimates fall by 10%

Executive VP & Chief Strategy Officer notifies of intention to sell stock

Price target decreased to US$114

Analyst Forecasts Just Became More Bearish On Horizon Therapeutics Public Limited Company (NASDAQ:HZNP)

Horizon Therapeutics Public Limited Company Reports Impairment of Goodwill for the Second Quarter Ended June 30, 2022

Do Horizon Therapeutics' (NASDAQ:HZNP) Earnings Warrant Your Attention?

Horizon Therapeutics: Buy The Dip For Slightly Risky, Catalyst Driven Growth

FDA Approves KRYSTEXXA® (pegloticase) Injection Co-Administered With Methotrexate, Expanding the Labeling to Help More People with Uncontrolled Gout Achieve a Complete Response to Therapy

Horizon gets FDA approval for Krystexxa's use with methotrexate for uncontrolled gout

Horizon Therapeutics Public Limited Company to Report Q2, 2022 Results on Aug 03, 2022

Horizon Therapeutics Public Limited Company Announces New Analysis Finds UPLIZNA (inebilizumab) Effective Among European Populations with Neuromyelitis Optica Spectrum Disorder (NMOSD)

Executive VP & Chief Strategy Officer notifies of intention to sell stock

Horizon Therapeutics plc Submits Regulatory Filing for Uplizna® (Inebilizumab) in Brazil

Horizon Therapeutics Public Limited Company Announces Results of A New Analysis Examining Rates of Hyperglycemia Among Patients Treated with TEPEZZA for TED Compare to Placebo in the Phase 2 and OPTIC Phase 3 Clinical Trials

Desglose de ingresos y gastosBeta

Historial de beneficios e ingresos

Análisis del flujo de caja libre vs. Beneficios

Análisis del crecimiento de los beneficios en el pasado

Rentabilidad financiera

Rentabilidad económica

Rendimiento del capital invertido

Desglose de ingresos y gastos
Beta